Alsheikh-Ali AA, Karas RH. Journal of Clinical Lipidology 2009;3:138-142.

Slides:

Advertisements

Similar presentations

Clinical Effectiveness Dr. Shahram Yazdani Associate Professor of SBUMS.

Advertisements

Time line of data collection in the Nurses’ Health Study, 1988 to 2000 A. Heather Eliassen et al, Arch Intern Med. 2005; 165:

SHARP trial Study of Heart and Renal Protection : a randomised placebo-controlled trial The e ﬀ ects of lowering LDL cholesterol with simvastatin plus.

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

Background and Objective In the recently reported Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial, the combination of ezetimibe/simvastatin (E/S)

STATINS AGAIN. Atorvastatin Off patent Atorvastatin 40 = £36 PA Simvastatin 40 = £14 PA Atorvastatin 80 = £72 PA Simvastatin 80 = £24 PA.

What’s the point of Ezetimibe? MeReC dio/cdlipids/merec_extra_no47.html.

Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.

High-dose ARB monotherapy versus ARB/CCB combination on cardiovascular events in Japanese elderly high-risk hypertensive patients. The OSCAR trial Ogawa.

Pharmacogenetics.

4S: Scandinavian Simvastatin Survival Study

Demographic Characteristics of Individuals With AERS of Rhabdomyolysis, Proteinuria/Nephropathy, or Renal Failure (COMPOSITE AERS) Alsheikh-Ali AA et al.

Definition of measurements and patients Michael J. Murphy, et al. Br J Clin Pharmacol 2008;65:

Alcohol, Other Drugs, and Health: Current Evidence

Rates of Ambulatory Care Visits for Treating Adverse Drug Events (VADEs): Trend 1995–2001 Data: National Ambulatory Medical Care Survey and National Hospital.

Cost-Sharing for Plans Offered in the Federal Marketplace for 2018

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Presented By Luca Malorni at 2017 ASCO Annual Meeting

Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels† Eli.

A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT) Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Tips Need to Consider When Organizing a College Event

An Endocrinology Clinic in Dyslipidemia

A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin.

Applying New Data in Practice:

The Chemical Differences Between EPA and DHA.

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis Alan Menter,

The Chemical Differences Between EPA and DHA.

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients Evan Stein, MD, Harold Bays, MD, Michael Koren,

LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?

An Update on PCSK9 Inhibitors

ماجستير إدارة المعارض من بريطانيا

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Drug cycling with collateral sensitivity

CGRP Antibodies in Migraine

A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia Gisle Langslet, MD, Andrei Breazna, PhD, Euridiki.

Chest pain in achalasia: Patient characteristics and clinical course

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance

Toxicity spectra and rankings in the subgroup analysis based on each specific grade 1-5 adverse event and cancer type. Toxicity spectra and rankings in.

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary Terry A. Jacobson, MD, Matthew.

Advances in Hypertriglyceridemia Treatment

Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States Sudhir K. Unni, PhD, MBA, Ruben G.W.

Ezetimibe/simvastatin

LDL Cholesterol.

Extraordinary Cases in VTE

Flow of Patients Through the Trial

Characteristics of the Patients at Baseline*

Lipid Updates From Spring 2019

Familial hypercholesterolemia in a European Mediterranean population—Prevalence and clinical data from 2.5 million primary care patients Alberto Zamora,

An Update on PCSK9 Inhibitors

Switch to RAL-containing regimen

Addressing Cardiovascular Events:

Characteristics of Large Randomized Controlled Statin Trials Included in the Present Analysis Alawi A. et al. JACC 2008 Aug 20 [Epub ahead of print]

Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia Martine Paquette, MSc, Sophie.

Updates on Dyslipidemia

The ACCORD Study Group. NEJM 2010; Epub March 14

BETONLINEBETONLINE A·+A·+

Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.

Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)

A Clinical Pharmacist Patient-Safety Initiative to Reduce Against-Label Prescribing of Statins with Cyclosporine Donald G. Lamprecht, PharmD, Anne M.

Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol—The role of LDL-apheresis Mary P. McGowan, MD, FNLA

Number of patients treated at clinics that followed up fewer than 10 patients (2013–2016) or 20 patients (2012) and proportion of patients followed up.

Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia Anna.

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary Terry A. Jacobson, MD, Matthew.

Antitumor activity of AMG 102 in combination with bevacizumab or motesanib. Antitumor activity of AMG 102 in combination with bevacizumab or motesanib.

Representativeness of linked cancer registry and dispensed prescription data as compared with cancer registry data alone, by key patient and tumour characteristics.

Presentation transcript:

Alsheikh-Ali AA, Karas RH. Journal of Clinical Lipidology 2009;3:

Characteristics of cancer-associated adverse event reports Alsheikh-Ali AA, Karas RH. Journal of Clinical Lipidology 2009;3:

(A) Rates of cancer adverse event reports in patients treated with the combination ezetimibe/simvastatin and other potent cholesterol-lowering drugs (B) The proportion of cancer adverse event reports relative to all reported adverse events in patients treated with the combination ezetimibe/simvastatin and other potent cholesterol lowering drugs *P<.01 versus ezetimibe/simvastatin. †P<.01 versus ezetimibe Alsheikh-Ali AA, Karas RH. J Clin Lip 2009;3:

Rates of cancer associated adverse event reports in patients treated with the combination ezetimibe/simvastatin (E/S) and other potent cholesterol lowering drugs (rate per million prescriptions) Alsheikh-Ali AA, Karas RH. Journal of Clinical Lipidology 2009;3: